Improving known classes of antibiotics: An optimistic approach for the future

Current Opinion in Pharmacology

Volumn 12, Issue 5, 2012, Pages 527-534

  Bush, Karen ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; AVIBACTAM; BAL 30072; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFTAROLINE; CEFTAZIDIME; CEFTOBIPROLE; CEFTOLOZANE; CEPHALOSPORIN; CETHROMYCIN; CLAVULANIC ACID; CXA 201; DELAFLOXACIN; IMIPENEM; JNJ Q2; MACROLIDE; MK 7655; NEMONOXACIN; NEOGLYCOSIDE; OMADACYCLINE; OXAZOLIDINONE DERIVATIVE; PLAZOMICIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RADEZOLID; SOLITHROMYCIN; SULBACTAM; TAZOBACTAM; TEDIZOLID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIAL PNEUMONIA; BACTERIAL SKIN DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DIABETIC FOOT; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; URINARY TRACT INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE; HUMANS;

EID: 84867330853     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.06.003     Document Type: Review

References (57)

1. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, M. Scheld, B. Spellberg, and J. Bartlett Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin Infect Dis 48 2009 1 12
2. K. Bush, P. Courvalin, G. Dantas, J. Davies, B. Eisenstein, P. Huovinen, G.A. Jacoby, R. Kishony, B.N. Kreiswirth, and E. Kutter Tackling antibiotic resistance Nat Rev Microbiol 9 2011 894 896
3. D.M. Livermore Fourteen years in resistance Int J Antimicrob Agents 39 2012 283 294
4. C. Walsh Where will new antibiotics come from? Nat Rev Microbiol 1 2003 65 70
5. M.N. Gwynn, A. Portnoy, S.F. Rittenhouse, and D.J. Payne Challenges of antibacterial discovery revisited Ann NY Acad Sci 1213 2010 5 19
6. L.L. Silver Challenges of antibacterial discovery Clin Microbiol Rev 24 2011 71 109
7. D. Andes, J. Anon, M.R. Jacobs, and W.A. Craig Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections Clin Lab Med 24 2004 477 502
8. J.B. Aggen, E.S. Armstrong, A.A. Goldblum, P. Dozzo, M.S. Linsell, M.J. Gliedt, D.J. Hildebrandt, L.A. Feeney, A. Kubo, and R.D. Matias Synthesis and spectrum of the neoglycoside ACHN-490 Antimicrob Agents Chemother 54 2010 4636 4642
9. R.T. Cass, C.D. Brooks, N.A. Havrilla, K.J. Tack, M.T. Borin, D. Young, and J.B. Bruss Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects Antimicrob Agents Chemother 55 2011 5874 5880
10. D.M. Livermore, S. Mushtaq, M. Warner, J.C. Zhang, S. Maharjan, M. Doumith, and N. Woodford Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates J Antimicrob Chemother 66 2011 48 53
11. F.C. Tenover, I. Tickler, E.S. Armstrong, A. Kubo, S. Lopez, D.H. Persing, and G.H. Miller Activity of ACHN-490 against methicillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals Int J Antimicrob Agents 38 2011 352 354
12. D. Landman, P. Kelly, M. Backer, E. Babu, N. Shah, S. Bratu, and J. Quale Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City J Antimicrob Chemother 66 2011 332 334
13. M.G.P. Page, and J. Heim New molecules from old classes: revisiting the development of beta-lactams Idrugs 12 2009 561 565
14. K. Bush, M. Heep, M.J. Macielag, and G.J. Noel Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy Expert Opin Investig Drugs 16 2007 419 429
15. J.A. Karlowsky, H.J. Adam, M.R. Decorby, P.R. Lagace-Wiens, D.J. Hoban, and G.G. Zhanel In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients in Canadian hospitals in 2009 Antimicrob Agents Chemother 55 2011 2837 2846
16. H.S. Sader, P.R. Rhomberg, D.J. Farrell, and R.N. Jones Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes Antimicrob Agents Chemother 55 2011 2390 2394
17. P. Hebeisen, I. Heinze-Krauss, P. Angehrn, P. Hohl, M.G. Page, and R.L. Then In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci Antimicrob Agents Chemother 45 2001 825 836
18. M.G. Page Anti-MRSA beta-lactams in development Curr Opin Pharmacol 6 2006 480 485
19. S. Mushtaq, M. Warner, G. Williams, I. Critchley, and D.M. Livermore Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae J Antimicrob Chemother 65 2010 1428 1432
20. T. Stachyra, M.C. Pechereau, J.M. Bruneau, M. Claudon, J.M. Frere, C. Miossec, K. Coleman, and M.T. Black Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-beta-lactam beta-lactamase inhibitor Antimicrob Agents Chemother 54 2010 5132 5138
21. A. Endimiani, K.M. Hujer, A.M. Hujer, M.E. Pulse, W.J. Weiss, and R.A. Bonomo Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae Antimicrob Agents Chemother 55 2011 82 85
22. D.E. Wiskirchen, J.L. Crandon, G.H. Furtado, G. Williams, and D.P. Nicolau In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae Antimicrob Agents Chemother 55 2011 3220 3225
23. D.M. Livermore, S. Mushtaq, K. Barker, R. Hope, M. Warner, and N. Woodford Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104) J Antimicrob Chemother 67 2012 1354 1358
24. E. Titelman, I.M. Karlsson, Y. Ge, and C.G. Giske In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae Diagn Microbiol Infect Dis 70 2011 137 141
25. P. Bhagunde, K.-T. Chang, E.B. Hirsch, K.R. Ledesma, M. Nikolaou, and V.H. Tam A novel modeling framework to guide design of optimal dosing strategies for beta-lactamase inhibitors Antimicrob Agents Chemother 56 2012 2237 2240
26. K. Bush, and J.F. Fisher Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from Gram-negative bacteria Annu Rev Microbiol 65 2011 455 478
27. M.G.P. Page, C. Dantier, and E. Desarbre In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli Antimicrob Agents Chemother 54 2010 2291 2302
28. M.E. Flanagan, S.J. Brickner, M. Lall, J. Casavant, L. Deschenes, S.M. Finegan, D.M. George, K. Granskog, J.R. Hardink, and M.D. Huband Preparation, Gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols ACS Med Chem Lett 2 2011 385 390
29. S. Han, R.P. Zaniewski, E.S. Marr, B.M. Lacey, A.P. Tomaras, A. Evdokimov, J.R. Miller, and V. Shanmugasundaram Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa Proc Natl Acad Sci U S A 107 2010 22002 22007
30. P.G. Higgins, D. Stefanik, M.G.P. Page, M. Hackel, and H. Seifert In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non-susceptible Acinetobacter baumannii J Antimicrob Chemother 67 2012 1167 1169
31. T.A. Russo, M.G. Page, J.M. Beanan, R. Olson, A.M. Hujer, K.M. Hujer, M. Jacobs, S. Bajaksouzian, A. Endimiani, and R.A. Bonomo In vivo and in vitro activity of the siderophore monosulfactam BAL30072 against Acinetobacter baumannii J Antimicrob Chemother 66 2011 867 873
32. H. Nikaido, and E.Y. Rosenberg Cir and Fiu proteins in the outer membrane of Escherichia coli catalyze transport of monomeric catechols: study with beta-lactam antibiotics containing catechol and analogous groups J Bacteriol 172 1990 1361 1367
33. D.J. Hoban Prevalence and characterization of macrolide resistance in clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes from North America J Chemother 3 2002 25 30
34. R.M. Echols Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world Ann NY Acad Sci 1 2011 153 161
35. D. Bertrand, S. Bertrand, E. Neveu, and P. Fernandes Molecular characterization of off-target activities of telithromycin: a potential role for nicotinic acetylcholine receptors Antimicrob Agents Chemother 54 2010 5399 5402
36. J.A. Sutcliffe Antibiotics in development targeting protein synthesis Ann NY Acad Sci 1 2011 122 152
37. D.J. Farrell, M. Castanheira, H.S. Sader, and R.N. Jones The in vitro evaluation of solithromycin (CEM-101) against pathogens isolated in the United States and Europe (2009) J Infect 61 2010 476 483
38. S.D. Putnam, H.S. Sader, D.J. Farrell, D.J. Biedenbach, and M. Castanheira Antimicrobial characterisation of solithromycin (CEM-101), a novel fluoroketolide: activity against staphylococci and enterococci Int J Antimicrob Agents 37 2011 39 45
39. J.B. Locke, J. Finn, M. Hilgers, G. Morales, S. Rahawi, G.C. Kedar, J.J. Picazo, W. Im, K.J. Shaw, and J.L. Stein Structure-activity relationships of diverse oxazolidinones for linezolid-resistant Staphylococcus aureus strains possessing the cfr methyltransferase gene or ribosomal mutations Antimicrob Agents Chemother 54 2010 5337 5343
40. I. Rodriguez-Avial, E. Culebras, C. Betriu, G. Morales, I. Pena, and J.J. Picazo In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci J Antimicrob Chemother 67 2012 167 169
41. S. Lemaire, K. Kosowska-Shick, P.C. Appelbaum, G. Verween, P.M. Tulkens, and B.F. Van Cellular pharmacodynamics of the novel biaryloxazolidinone radezolid: studies with infected phagocytic and nonphagocytic cells, using Staphylococcus aureus, Staphylococcus epidermidis, Listeria monocytogenes, and Legionella pneumophila Antimicrob Agents Chemother 54 2010 2549 2559
42. S. Lemaire, P.M. Tulkens, and B.F. Van Cellular pharmacokinetics of the novel biaryloxazolidinone radezolid in phagocytic cells: studies with macrophages and polymorphonuclear neutrophils Antimicrob Agents Chemother 54 2010 2540 2548
43. P. Prokocimer, P. Bien, J. Surber, P. Mehra, C. DeAnda, J.B. Bulitta, and G.R. Corey A phase 2 randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections (cSSSI) Antimicrob Agents Chemother 55 2011 583 592
44. K.J. Shaw, and M.R. Barbachyn The oxazolidinones: past, present, and future Ann NY Acad Sci 1 2011 48 70
45. S. Lemaire, P.M. Tulkens, and B.F. Van Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-Gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus Antimicrob Agents Chemother 55 2011 649 658
46. T.L. Lauderdale, Y.R. Shiau, J.F. Lai, H.C. Chen, and C.H. King Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates Antimicrob Agents Chemother 54 2010 1338 1342
47. B.J. Morrow, W. He, K.M. Amsler, B.D. Foleno, M.J. Macielag, A.S. Lynch, and K. Bush In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone Antimicrob Agents Chemother 54 2010 1955 1964
48. B.J. Morrow, D. Abbanat, E.Z. Baum, S.M. Crespo-Carbone, T.A. Davies, W. He, W. Shang, A.M. Queenan, and A.S. Lynch Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2 Antimicrob Agents Chemother 55 2011 5512 5521
49. C.C. Lai, W.L. Liu, W.C. Ko, Y.H. Chen, H.R. Tan, Y.T. Huang, and P.R. Hsueh Multicenter study in Taiwan of the in vitro activities of nemonoxacin, tigecycline, doripenem, and other antimicrobial agents against clinical isolates of various Nocardia species Antimicrob Agents Chemother 55 2011 2084 2091
50. J.C. Yang, P.I. Lee, and P.R. Hsueh In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007 Eur J Clin Microbiol Infect Dis 29 2010 1369 1375
51. D.J. van Rensburg, R.P. Perng, I.H. Mitha, A.J. Bester, J. Kasumba, R.G. Wu, M.L. Ho, L.W. Chang, D.T. Chung, and Y.T. Chang Efficacy and safety of nemonoxacin versus levofloxacin for community-acquired pneumonia Antimicrob Agents Chemother 54 2010 4098 4106
52. P. Covington, J.M. Davenport, D. Andrae, W. O'Riordan, L. Liverman, G. McIntyre, and J. Almenoff Randomized, double-blind, Phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection Antimicrob Agents Chemother 55 2011 5790 5797
53. P.J. Petersen, N.V. Jacobus, W.J. Weiss, P.E. Sum, and R.T. Testa In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936) Antimicrob Agents Chemother 43 1999 738 744
54. E. Tasina, A.B. Haidich, S. Kokkali, and M. Arvanitidou Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis Lancet Infect Dis 11 2011 834 844
55. M. Hornsey, M.J. Ellington, M. Doumith, S. Hudson, D.M. Livermore, and N. Woodford Tigecycline resistance in Serratia marcescens associated with up-regulation of the SdeXY-HasF efflux system also active against ciprofloxacin and cefpirome J Antimicrob Chemother 65 2010 479 482
56. A. Ruzin, F.W. Immermann, and P.A. Bradford RT-PCR and statistical analyses of adeABC expression in clinical isolates of Acinetobacter calcoaceticus-Acinetobacter baumannii complex Microb Drug Res Mech 16 2010 87 89
57. T. Horiyama, E. Nikaido, A. Yamaguchi, and K. Nishino Roles of Salmonella multidrug efflux pumps in tigecycline resistance J Antimicrob Chemother 66 2011 105 110